01/09/2020 – AB Science announces the results of the Combined Shareholders’ Meeting of August 31, 2020 Post navigationPreviousPrevious post:New results published in Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s DiseaseNextNext post:New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitroRelated PostsBoursorama interview of Alain Moussy, CEO of AB ScienceDecember 23, 2020Capital raise for a total amount of 15 million eurosDecember 21, 2020Results from phase 2B/3 study evaluating masitinib in Alzheimer’s diseaseDecember 18, 2020Masitinib in Alzheimer’s Disease Webcast PresentationDecember 17, 2020Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020December 17, 2020Corrective press release regarding adverse events information from study AB09004December 17, 2020